This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy

This study has been completed.
Sponsor:
Collaborator:
Urology of Virginia
Information provided by (Responsible Party):
Matthew Dunn, University of Southern California
ClinicalTrials.gov Identifier:
NCT02122341
First received: April 18, 2014
Last updated: March 22, 2017
Last verified: March 2017
  Purpose
The purpose of this clinical study is to evaluate BackStop, a polymer-based device that is intended to be used during ureteroscopic lithotripsy to prevent retrograde stone migration.

Condition Intervention
Kidney Stones Device: BackStop

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant
Primary Purpose: Treatment
Official Title: Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial

Further study details as provided by Matthew Dunn, University of Southern California:

Primary Outcome Measures:
  • Rate of prevention of retrograde stone or stone fragment migration [ Time Frame: At the time of surgery ]

Secondary Outcome Measures:
  • Stone-free rate [ Time Frame: 2 months ]

Other Outcome Measures:
  • Need for secondary procedures [ Time Frame: Up to 3 months ]
  • Time for BackStop injection [ Time Frame: During Surgery ]
  • Duration of lithotripsy procedure [ Time Frame: during surgery ]

Enrollment: 35
Study Start Date: April 2014
Study Completion Date: July 2016
Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BackStop
Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
Device: BackStop
BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
No Intervention: Control
Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.

Detailed Description:

During ureteroscopic treatment for ureteral stones, lithotripsy, irrigation, and manipulation of the stone often pushes stone away into the kidney itself. This phenomenon is called retropulsion, which is defined as clinically significant retrograde migration of stone or stone fragments. Movement of stones retrograde into the renal pelvis could potentially add and complicate the surgery further. Often scopes need to be changed in order to reach the stone, and chasing these stones will add time to the surgery and require more valuable resources. Furthermore, sometimes a second operation will need to be done when these retropulsed fragments could not be all found and cleaned out.

A number of devices have been developed to prevent such migration including stone baskets and conical devices. These are wire-based devices which have the potential of injuring the ureter. Because of safety concerns and that there is limited data available on the effectiveness of these devices; these are not widely used by urologists. BackStop has recently been developed as another tool to prevent retropulsion. It is a water soluble gel that is injected proximal to the stone. This creates a physical barrier that prevents stone migration during ureteroscopic lithotripsy for ureteral calculus.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patient with solitary ureteral stone ranging from 5mm to 15mm diameter
  • able to tolerate general anesthesia
  • clinical indication for treatment by ureteroscopic lithotripsy
  • must be willing and able to participate in any follow-up visits
  • provide informed consent
  • have a CT scan demonstrating the stone

Exclusion Criteria:

  • patients undergoing extracorporeal shock wave lithotripsy (ESWL) or any other extracorporeal or percutaneous lithotripsy procedure as primary procedure
  • any co-morbidity or condition that would necessitate exclusion of patient (physician opinion)
  • renal or ureteral anatomical abnormality
  • multiple stones in the indicated ureter
  • stones in the indicated kidney
  • patient is immunocompromised
  • multiple organ dysfunction syndrome
  • has an absolute or relative solitary kidney mass
  • >= Stage 3 chronic kidney disease
  • bilateral ureteral obstructing stones
  • staghorn calculi
  • impaction of several stone fragments (Steinstrasse)
  • uncorrected coagulopathy/thrombocytopenia
  • urethral and/or ureteral stricture
  • reconstructive urinary surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02122341

Locations
United States, California
USC Institute of Urology
Los Angeles, California, United States, 90089
United States, Virginia
Urology of Virginia
Virginia Beach, Virginia, United States, 23462
Sponsors and Collaborators
University of Southern California
Urology of Virginia
Investigators
Principal Investigator: Matthew Dunn, M.D. USC Institute of Urology
  More Information

Additional Information:
Publications:

Responsible Party: Matthew Dunn, Asst Professor of Clinical Urology, Director Endourology & Stone Disease, University of Southern California
ClinicalTrials.gov Identifier: NCT02122341     History of Changes
Other Study ID Numbers: HS-12-00714
Study First Received: April 18, 2014
Last Updated: March 22, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Kidney Calculi
Nephrolithiasis
Kidney Diseases
Urologic Diseases
Urolithiasis
Urinary Calculi
Calculi
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on June 28, 2017